CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Standard Chartered Expands Hedge Fund Access for Wealth Clients 
REPAY Stock Rises After Visa Platform Connect Collaboration 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
SK Hynix Shares Surge on Record $28.6 Billion Buyback 
Samsung Eyes $72 Billion Shareholder Return Plan as AI Chip Boom Fuels Profits 
Barclays Downgrades Renault as Cost Savings Challenges Grow 
SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
Coty Revenue Beats Estimates as Beauty Demand Holds Firm 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
Moody’s Upgrades Vodafone Hybrid Debt Ratings to Baa3 
Add as a preferred source on Google
LAWRENCEVILLE, N.J., May 04, 2018 -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended March 31, 2018 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system at 11:00 a.m. EDT on Friday, May 11, 2018. To participate in the call, interested parties may dial 1-888-298-3457 (Toll-Free/North America) or 1-719-325-4917 (International/Toll) and ask for the Celsion Corporation 1st Quarter 2018 Earnings Call (Conference Code: 6550185) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live over the internet at www.celsion.com.
The call will be archived for replay on Friday, May 11, 2018 and will remain available until Friday, May 25, 2018. The replay can be accessed at 1-888-203-1112 (Toll-Free/USA) or 1-719-457-0820 (International/Toll) using Conference ID: 6550185. An audio replay of the call will also be available on the Company’s website, www.celsion.com, for 90 days after 2:00 p.m. EDT on Friday, May 11, 2018.
About Celsion Corporation
Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in development for other cancer indications. The Company’s product pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. For more information on Celsion, visit our website: http://www.celsion.com. (CLSN-FIN).
Celsion Investor Contact Jeffrey W. Church Sr. Vice President and CFO 609-482-2455 [email protected]
